ANTIBIOTIC-ASSOCIATED DIARRHEA: ISSUES OF THERAPEUTIC PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article covers the basics of the pathogenesis and clinical course of antibiotic-associated diarrhea (AAD) which is one of the serious adverse events during antibiotic therapy. Increased risk of AAD is associated with the use of cephalosporins, clindamycin or penicillins broad-spectrum. Currently, in terms of prevention and treatment of AAD, the leading role belongs to probiotics. The key in therapeutic tactics in the treatment of patients requiring antibiotic therapy is early, from the beginning of the use of antibiotics, appointment of probiotics. Doctors should be guided by knowledge of the properties of the strains included in the probiotic preparation and prescribe the drug in sufficient therapeutic dosage for at least 2-3 weeks after completion of antibiotic therapy. Among the well-studied probiotics with proven effectiveness in the prevention and treatment of AAD are Bifidobacterium animalis, subspecies lactis BB-12, and Lactobacillus acidophilus (LA-5). This probiotic complex is represented in modern probiotic drug Linex Forte, each capsule of which contains at least 2x109 CFU of lyophilized live bacteria L. acidophilus [LA-5]and B. animalis (lactis BB-12].

Full Text

Restricted Access

About the authors

Antonina Aleksandrovna Ploskireva

Central Research Institute of Epidemiology

Email: antonina@ploskireva.com
PhD, Associate Professor, Senior Researcher at the Department of Clinical Infectious Pathology 111123, Moscow, 3a Novogireevskaya St

References

  1. Горелов А.В., Усенко Д.В. Современные подходы к профилактике антибиотико-ассоциированной диареи у детей. Consilium Medicum. 2005;2. Приложение по педиатрии.
  2. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 1998;16:292-307.
  3. Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., Englund G., Nord C.E., Svenungsson B. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 2001;47:43-50.
  4. Elstner C.L., Lindsay A.N., Book L.S., Matsen J.M. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhoea in children. Pediatr. Inf. Dis. 1983;2:364-6.
  5. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., Lacombe A., Rembert F., Toursel F., Bernasconi P., Gottrand F., McFarland L.V., Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J. Pediatr. Gastroenterol. Nutr. 2003;37:22-6.
  6. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardiiin the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 2005;21:583-90.
  7. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile. Клиническая микробиология и антимикробная химиотерапия. 2002;3(4):200-32.
  8. Плоскирева А.А., Горелов А.В. Системный подход к оценке микробиоценоза желудочно-кишечного тракта при острых кишечных инфекциях у детей. Современные проблемы науки и образования. 2015;5. URL: http://www.science-education.ru/ru/article/ view?id=22040 (дата обращения: 17.04.2016).
  9. Beaugerie L., Petit J.C. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhea. Best Pract. Res. Clin. Gastroenterol. 2004;18:337-52.
  10. Clausen M.R., Bonnen H., Tvede M., Mortensen P.B. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterology. 1991;101:1497-504.
  11. Asha N.J., Tompkins D., Wlilcox M.H. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringensand Staphylococcus aureus. J. Clin. Microbiol. 2006;44:2785-91.
  12. Hogenauer C., Langner C., Beubler E. Klebsiella oxytocaas a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 2006;355:2418-26.
  13. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin. Infect. Dis. 1998;27:702-10.
  14. Thomas M.R., Litin S.C., Osmon D.R., Corr A.P., Weaver A.L., Lohse C.M. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin. Proc. 2001;76:883-9.
  15. Ивашкин В.Т., Шептулин А.А. Синдром диареи. М.: ГЭОТАР-Медицина, 2000. 135 с. [Ivashkin V.T., Sheptulin A.A. Diarrheal Syndrome. Moscow: GEOTAR-Medicine, 2000. 135 p. (in Russian)]
  16. Floch M.H. Recommendations for Probiotic Use in Humans - 2014 Update. Pharmaceuticals. (Basel) 2014;7(10):999-1007.
  17. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006;101:812-22.
  18. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic-associated diarrhoea: meta-analysis. Br. Med. J. 2002;324:1361-4.
  19. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., Gasbarrini А. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol. Ther. 2002;16:1461-7.
  20. Szajewska H., Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardiiin the prevention of antibiotic-associated diarrhea. Aliment Pharmacol. Ther. 2005;22:365-72.
  21. Hawrelak J.A., Whitten D.L., Myers S.P. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion. 2005;72:51-6.
  22. Bhalla A. Randomized placebo-controlled, double blind, multicentric trial on efficacy and safety of providac techsules (Lactobacillus Acidophilus LA-5 and Bifidobacterium BB-12) for prevention of antibiotic-associated diarrhea in Indian patients [in: Abstracts: 40th Annual Meeting of the American college of clinical pharmacology; September 11-13, 2011; Chicago, IL]. J. Clin. Pharmacol. 2011;51(9):1327.
  23. Chatterjee S., Kar P., Das T., Ray S., Gangulyt S., Rajendiran C., Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J. Assoc. Physicians. India. 2013;61(10):708-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies